Kaku K, et al. - Researchers enquired regarding the safety and efficacy of once-weekly subcutaneous semaglutide as a monotherapy or combined with an oral antidiabetic drug (OAD) vs an additional OAD added to background therapy in Japanese people with type 2 diabetes (T2D) inadequately controlled on diet/exercise or OAD monotherapy. Findings demonstrated more adverse events (AEs) in the semaglutide 0.5 mg (86.2%) and 1.0 mg (88.0%) groups than in the additional OAD group (71.7%). It was inferred that semaglutide was well tolerated, without any new safety issues. It considerably reduced HbA1c and body weight vs additional OAD treatment in Japanese people with T2D.